Related Experiment Video
Updated: Aug 9, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
Xukai Luo1, Yini Shen1, Wu Huang1
1Department of Gynecologic Oncology, 92276Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Abstract:
Among the three primary gynecological malignancies, ovarian cancer has the lowest incidence but the worst prognosis. Because of the poor prognosis of ovarian cancer patients treated with existing treatments, immunotherapy is emerging as a potentially ideal alternative to surgery, chemotherapy, and targeted therapy. Among immunotherapies, immune checkpoint inhibitors have been the most thoroughly studied, and many drugs have been successfully used in the clinic. CD47, a novel immune checkpoint, provides insights into ovarian cancer immunotherapy. This review highlights the mechanisms of tumor immune evasion via CD47-mediated inhibition of phagocytosis and provides a comprehensive insight into the progress of the relevant targeted agents in ovarian cancer.
Insights
Ovarian cancer has a poor prognosis, driving research into immunotherapy. CD47, a novel immune checkpoint, shows promise in targeting ovarian cancer by blocking tumor immune evasion and phagocytosis inhibition.
Area of Science:
- Gynecologic Oncology
- Immunotherapy
- Cancer Immunology
Background:
- Ovarian cancer, despite lower incidence, presents the worst prognosis among gynecologic malignancies.
- Current treatments like surgery and chemotherapy have limited efficacy, necessitating novel therapeutic strategies.
- Immunotherapy, particularly immune checkpoint inhibitors, offers a promising alternative for ovarian cancer treatment.
Purpose of the Study:
- To review the mechanisms of CD47-mediated tumor immune evasion in ovarian cancer.
- To provide a comprehensive overview of targeted agents against CD47 in ovarian cancer.
- To highlight CD47 as a potential therapeutic target for improving ovarian cancer immunotherapy.
Main Methods:
- Literature review of studies on CD47 and ovarian cancer.
- Analysis of mechanisms underlying CD47-mediated immune evasion.
- Evaluation of the progress of CD47-targeted agents in preclinical and clinical settings.
Main Results:
- CD47 acts as a novel immune checkpoint, inhibiting phagocytosis and promoting tumor immune evasion in ovarian cancer.
- Targeting CD47 disrupts this immune evasion, potentially enhancing anti-tumor immune responses.
- Several agents targeting CD47 are under investigation for their efficacy in ovarian cancer.
Conclusions:
- CD47 represents a significant target for overcoming immune evasion in ovarian cancer.
- Targeted therapies against CD47 hold potential for improving immunotherapy outcomes in ovarian cancer patients.
- Further research into CD47-based strategies is crucial for advancing ovarian cancer treatment.
